We serve Chemical Name:metixene CAS:4969-02-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:metixene
CAS.NO:4969-02-2
Synonyms:Tremonil
Molecular Formula:C20H23NS
Molecular Weight:309.46800
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:bp0.07 171-175°
Density:N/A
Index of Refraction:
PSA:28.54000
Exact Mass:309.15500
LogP:4.95290
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Tremonil chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Tremonil physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Tremonil Use and application,Tremonil technical grade,usp/ep/jp grade.
Related News: Franco Stevanato, Giovanni’s 48-year-old grandson and the company’s executive chairman since stepping down as CEO in February, had his grandfather’s vision in mind when he virtually rang the opening bell on Wall Street on Tuesday. n-methyl-4-(p-formylstyryl)pyridinium methylsulfate manufacturers Franco Stevanato, Giovanni’s 48-year-old grandson and the company’s executive chairman since stepping down as CEO in February, had his grandfather’s vision in mind when he virtually rang the opening bell on Wall Street on Tuesday. tert-Butyl 5-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate suppliers Lonza is investing CHF 20 million in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investment will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers. 3-Chloropyridine vendor & factory Grégoire holds a Masters’ degree in Fundamental Physics from Pierre and Marie Curie University.,ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged.
